We did not examine the pharmacokinetics of anti-PD-L1 antibodies, but the research indicates that 70% of anti-PD-L1 IgG was lost from circulation 7 days after injection in tumor-bearing mice with high anti-PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.